|
| Monday, November 9, 2020 |
|
|
Eisai: Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer's Disease Using Blood |
| Sysmex Corporation and Eisai Co., Ltd. announced that the most recent data from the project to develop a method of diagnosing Alzheimer's disease (AD) using blood plasma was presented at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference, held virtually from November 4 to 7, 2020. more info >> |
|
| Wednesday, October 28, 2020 |
|
|
Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer's Disease and Dementia at the 13th Clinical Trials on Alzheimer's Disease Conference |
| Eisai Co., Ltd. announced today that the company will conduct a total of 7 presentations, including the latest data of the investigational anti-amyloid beta (Abeta) protofibril antibody lecanemab (Development Code: BAN2401), at the 13th Clinical Trials on Alzheimer's Disease (CTAD) conference to be held virtually from November 4 to 7, 2020. more info >> |
|
|
Eisai and JD Health Establish JV Company in China to Implement Health Service Platform |
| Eisai Co., Ltd. and JD Health announced today that Eisai's Chinese subsidiary Eisai China Inc. and JD Health have established a joint venture company, Jingyi Weixiang (Shanghai) Health Industry Development Limited Company, to build a Health Service Platform for the elderly in China. more info >> |
|
| Monday, October 26, 2020 |
|
|
Eisai and Cogstate Expand Agreement for Global Development and Commercialization of Digital Cognitive Assessment Technologies |
| Eisai Co., Ltd. and Cogstate, Ltd. announced today that the companies have entered into a collaboration whereby Eisai has secured the global development rights and exclusive commercialization rights of all cognitive function tests developed by Cogstate, including the "Cogstate Brief BatteryTM" (CBB) for use in healthcare and other markets. more info >> |
|
| Friday, October 16, 2020 |
|
|
Eisai: Supplementary New Drug Applications for Anti-Epileptic Drug Fycompa as Monotherapy for Partial-Onset Seizures |
| Eisai Co., Ltd. announced today that the supplementary new drug applications for its in-house discovered and developed anti-epileptic drug (AED) Fycompa (generic name: perampanel) as monotherapy for partial-onset seizures and pediatric indication for partial onset seizures in patients with epilepsy 4 years or older have been accepted in China by the National Medical Products Administration. more info >> |
|
| Thursday, October 8, 2020 |
|
|
The University of Tokyo and Eisai Announce Research Collaboration for the Development and Drug Discovery of Targeted Protein Degradation Technology |
| The University of Tokyo and Eisai Co., Ltd. announced today a collaboration aiming for the development and drug discovery of targeted protein degradation technology has been created, with the establishment of a social cooperation program, "Protein Degradation Drug Discovery". more info >> |
|
| Tuesday, October 6, 2020 |
|
|
Eisai: Joint Development Agreement Aiming for Drug Discovery for COVID-19 Utilizing Eritoran and E6011 Concluded |
| In patients with COVID-19 due to the SARS-CoV-2 infection, severe cases such as acute respiratory distress syndrome (ARDS) and subsequent multiple organ failure have been reported. more info >> |
|
| Wednesday, September 30, 2020 |
|
|
Eisai and Seikagaku Enter into Agreement for the Marketing Alliance of SI-613, a Treatment of Osteoarthritis, in South Korea |
| Eisai and Seikagaku signed an agreement for the co-development and marketing alliance in China of SI-613 on April 1, 2020. more info >> |
|
| Monday, September 28, 2020 |
|
|
Eisai: Jyseleca (Filgotinib) Approved in Japan for Rheumatoid Arthritis |
| Gilead Japan will hold the marketing authorization of Jyseleca in Japan and will be responsible for the product supply of Jyseleca in Japan, while Eisai will be responsible for product distribution of Jyseleca in Japan in RA. more info >> |
|
| Wednesday, September 23, 2020 |
|
|
Eisai Receives Positive Opinion from EMA's CHMP on Use of Antiepileptic Agent Fycompa in Pediatric Patients |
| The CHMP's positive opinion is to extend the use of Fycompa as an adjunctive therapy for partial-onset seizures (POS) (with or without secondary generalization) by expanding the approved age range from 12 years and above to 4 years and above, and for primary generalized tonic-clonic seizures (PGTCS) from 12 years and above to 7 years and above. more info >> |
|
|
|
